Allogene Therapeutics Inc

General ticker "ALLO" information:

  • Sector: Health Care
  • Industry: Biotechnology
  • Capitalization: $457.2M

Allogene Therapeutics Inc does not follow the US Stock Market performance with the rate: -14.5%.

Estimated limits based on current volatility of 4.1%: low 1.82$, high 1.97$

Factors to consider:

  • Earnings for 9 months up through Q3 exceed our estimates

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2023-12-31 to 2025-12-30

  • 2023-12-31 to 2024-12-30 estimated range: [2.16$, 5.14$]
  • 2024-12-30 to 2025-12-30 estimated range: [2.42$, 5.47$]

Financial Metrics affecting the ALLO estimates:

  • Negative: Non-GAAP EPS, $ of -2.01 <= 0.10
  • Negative: Operating profit margin, % of -99.97 <= 1.03
  • Negative: Operating cash flow per share per price, % of -36.55 <= 2.35
  • Negative: negative Net income
  • Positive: Industry inventory ratio change (median), % of 0 <= 0
  • Positive: Interest expense per share, $ of 0 <= 0

Similar symbols

Short-term ALLO quotes

Long-term ALLO plot with estimates

Financial data

YTD 2021-12-31 2022-12-31 2023-12-31
Operating Revenue $38.49MM $0.24MM $0.10MM
Operating Expenses $294.28MM $335.69MM $327.83MM
Operating Income $-255.79MM $-335.45MM $-327.74MM
Non-Operating Income $-1.21MM $2.82MM $0.47MM
R&D Expense $220.18MM $256.39MM $242.91MM
Income(Loss) $-257.00MM $-332.63MM $-327.26MM
Profit(Loss) $-257.00MM $-332.63MM $-327.26MM
Stockholders Equity $916.41MM $665.87MM $512.23MM
Inventory $20.02MM $62.45MM $0.00MM
Assets $1,038.63MM $817.08MM $642.84MM
Operating Cash Flow $-184.81MM $-220.52MM $-237.73MM
Capital expenditure $21.45MM $5.19MM $1.52MM
Investing Cash Flow $163.66MM $106.16MM $163.29MM
Financing Cash Flow $11.96MM $2.95MM $95.69MM
Earnings Per Share* $-1.80 $-2.30 $-2.09

* EPS are Split Adjusted, recent splits may be reflected with a delay.